Article

Prolonged survival in a HER2 positive metastatic breast cancer patient with brain metastases treated with TDM1 after failure of next generation HER2 targeted therapies

2025-07-17

Abstract excerpt

<title>Abstract</title> <p><bold>Background:</bold> Brain metastases (BM) occur in up to 50% of patients with HER2-positive metastatic breast cancer (MBC) and represent a major clinical challenge due to limited CNS drug penetration. In recent years, novel anti-HER2 agents—such as trastuzumab deruxtecan (T-DXd) and tucatinib—have shown promising intracranial efficacy and are now recommended after progression on fi...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 3b979098-bf58-5df2-a0ca-9a6565d9e78c
DOI: 10.21203/rs.3.rs-6783648/v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Prolonged survival in a HER2 positive metastatic breast cancer patient with brain metastases treated with TDM1 after failure of next generation HER2 targeted therapiesDOI 10.21203/rs.3.rs-6783648/v1Read

LCCC 1025: a phase II study of everolimus, trastuzumab, and vinorelbine to treat progressive HER2-positive breast cancer brain metastases.Semantic proximity Read

Overcoming brain-derived therapeutic resistance in HER2+ breast cancer brain metastasisSemantic proximity Read

EGFR as a potent CAR T target in Triple Negative Breast Cancer Brain MetastasesSemantic proximity Read

Mechanism of action and resistance to Trastuzumab Deruxtecan in patients with metastatic breast cancer: the DAISY trialSemantic proximity Read

The efficacy and safety of pyrotinib in treating HER2-positive metastatic breast cancer patients:A multi-center studySemantic proximity Read

Trastuzumab Deruxtecan for ERBB2-Mutant Metastatic Non-Small Cell Lung Cancer With or Without Brain Metastases: A Secondary Analysis of Randomized Clinical Trials.Semantic proximity Read

Clinical and molecular features of resected breast cancer brain metastases: a single center retrospective cohort study.Semantic proximity Read

Systemic and Intracranial Efficacy and Safety of Trastuzumab Deruxtecan in Patients With HER2-Mutant NSCLC Across Treatment Lines: Evidence From the TRACER/HERTras Real-World Cohort.Semantic proximity Read

Treatment of brain metastases in the modern genomic era.Semantic proximity Read

Molecular subtyping of brain metastases and implications for therapy.Semantic proximity Read

Identification of targetable genomic profiling of breast cancer brain metastases identifies alterations and genomic signatures relevant to immune-checkpoint and PARP inhibitorsSemantic proximity Read

BRCA1 Mutations Associated With Increased Risk of Brain Metastases in Breast Cancer: A 1: 2 Matched-pair Analysis.Semantic proximity Read